Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

00 mg/2,500 mg, and one dose-limiting incident of diarrhea at 2,000 mg/2,500 mg) were transient and medically manageable. The most frequently reported treatment-related grade 2/3 adverse events were hand-foot syndrome (29 percent), leukopenia/neutropenia (24 percent) and fatigue (19 percent).

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modi
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... 15 Watermark Medical , Inc., a privately-held, ... market, has expanded the market reach of its Web-enabled ... three leading sleep solution providers in the U.S. and ... national provider of comprehensive sleep apnea services; Sleep ...
... Vista Partners announced today that it has updated ... Principal Analyst at Vista Partners stated, "Raptor is potentially ... a balanced pipeline of clinical and preclinical programs.  The ... programs and one Phase 3 trial with some indications ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading ... HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... bodybuilding and fitness site and the largest online retailer of nutritional supplements, ... BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... TAMPA, Florida (PRWEB) , ... August 03, 2015 ... ... Association for Physician Leadership ® and Navigant Center for Healthcare Research and Policy ... nationwide. , Fifty-five percent of respondents said they agreed or strongly agreed that ...
(Date:8/3/2015)... ... , ... A July 9 article from USA Today has revealed ... the American Dental Association. According to a study by the American Dental Association, from ... a single year to 2.2 million a year. Dentists and ADA officials all point ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... , This release is available in ... Patients suffering from two serious autoimmune disorders which ... cardiovascular disease, says a group of Montreal researchers. Dr. ... Institute of the McGill University Health Centre (RI-MUHC) have ...
... Additional Speakers and New Sessions Added to ... , , MINNEAPOLIS, Sept. 1 ... has added several speakers and new sessions to the most comprehensive ... Compliance and Ethics Institute, being held September 13 - 16, 2009, ...
... , , , ... Audiopoint, a leading provider of innovative voice data solutions, ... of automated patient management services. NotifierRx will help hospitals ... by automating outpatient follow-up with interactive voice-controlled services. , ...
... , , , OAKLAND, ... of the Thrive advertising campaign, with television, radio, print and online ... health of its members and the communities it serves. , ... -- illustrate Kaiser Permanente,s leadership in leveraging health information technology. As ...
... , , , , ... NTRI ), a leading provider of weight management programs ... to offer consumers striving for a late-summer shape up, some easy, top-of-mind ... long. , , According to Sansone, ...
... Industry Veteran to Lead PI Pharmaceutical Business Unit ... Physicians Interactive LLC (PI), a leader in digital sales and marketing ... Pingle has been named President of PI. Pingle will report to ... lead the company,s pharmaceutical business unit. , , ...
Cached Medicine News:Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 2Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 3Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 4Health News:Cynthia Cooper, Time Magazine's Person of the Year and former WorldCom Auditor to Address the 8th Annual Compliance and Ethics Institute, September 13-16, 2009, Planet Hollywood, Las Vegas, NV 5Health News:Audiopoint Adds Voice to Healthcare Reform Debate 2Health News:Audiopoint Adds Voice to Healthcare Reform Debate 3Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 4Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 5Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 6Health News:Physicians Interactive Names Sanjay Pingle President 2Health News:Physicians Interactive Names Sanjay Pingle President 3
... Markers have a unique squeezable barrel ... writing over wet prep solutions. Micro ... with optional rulers and sterile labels ... sterile, packaged individually in peel pouches. ...
Broad tip, gentian violet, sterile, disposable...
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: